Express Scripts DIR Fee Guide

Express Scripts is the second-largest PBM (owned by Cigna since 2018) and typically charges the second-highest DIR rate among major PBMs. 2024 industry median: 5.9% (NCPA data).

ESI's DIR structure emphasises generic effective rate (GER) more heavily than Caremark. Independents with lower generic dispensing rates or unfavourable generic mix disproportionately fail GER targets and pay elevated DIR.

ESI operates through several sub-networks with different DIR terms: SaveOnSP for specialty medications (different clawback structure), Accredo for infusion, and standard retail network for community pharmacies.

Express Scripts sets quarterly GER targets by therapeutic class. If your generic dispensing average falls below the target, ESI claws back the difference at reconciliation.

The trap: GER targets are based on network-wide medians, so independent pharmacies with unusual generic mix (higher brand percentage, specialty focus, older patient demographic) often miss GER even when dispensing appropriately for their patient population.

Median GER-related clawback for an ESI-network independent: $15K-$40K annually beyond base DIR rate.

1. Formal GER dispute process. ESI has a documented GER dispute process that many independents don't use. If your patient mix drives your generic dispensing rate below the target for legitimate clinical reasons, formal dispute (with documentation) can reduce or waive GER clawback. Success rate is ~40% when properly documented.

2. PSAO membership for ESI network. AmerisourceBergen Elevate has historically negotiated the best ESI terms for independents. Pharmacies moving from unaffiliated to Elevate report 15-25% ESI DIR reduction on average.

3. Cash-pay diversification. Every cash-pay Rx is 100% ESI-free — no DIR, no GER, no star-rating exposure. This is the same lever that works for Caremark and Optum, but ESI's heavier GER emphasis makes cash-pay diversification particularly high-leverage.